Protagenic Therapeutics Reports Net Income of $2.2 Million and Significant Asset Growth

Protagenic Therapeutics, Inc. has reported significant financial developments in its latest 10-Q filing for the period ending December 31, 2025. The company recorded a net income of $2.2 million for the three months ended December 31, 2025, a notable turnaround from a net loss of $850,287 during the same period in 2024. This shift is attributed to a substantial change in the fair value of derivative liabilities, which contributed $3.1 million to other income. However, for the nine months ending December 31, 2025, Protagenic reported a net loss of $3.7 million, compared to a loss of $1.8 million for the same period in 2024, primarily due to increased operating expenses.

The company's total assets surged to approximately $4.4 million as of December 31, 2025, up from $89,093 in March 2025, largely due to the acquisition of Phytanix Bio, which was completed in May 2025. This acquisition has expanded Protagenic's pipeline with five new preclinical drug candidates, enhancing its focus on treating stress-related neuropsychiatric and mood disorders. The company has also undergone a restructuring plan aimed at transitioning to a virtual operating model, which is expected to reduce annual operating expenses by approximately $8 million.

Operationally, Protagenic's employee headcount has been adjusted as part of its restructuring efforts, with a focus on retaining key personnel while reducing costs associated with preclinical activities. The company has also reported a working capital deficit of $4.5 million as of December 31, 2025, compared to $4.9 million in March 2025. This reflects ongoing challenges in managing cash flow, as the company continues to incur significant losses while advancing its clinical programs.

Looking ahead, Protagenic anticipates that its cash resources will be sufficient to fund operations until approximately the end of the second quarter of FY 2027. However, the company acknowledges the need for additional capital to support its ongoing development efforts and has expressed intentions to explore various financing options, including potential partnerships. The company is actively pursuing strategic alternatives for its preclinical programs, which may include partnerships or out-licensing arrangements to secure external funding.

In summary, Protagenic Therapeutics is navigating a complex financial landscape marked by significant operational changes and strategic acquisitions. While the company has made strides in its financial performance, it faces ongoing challenges related to cash flow and the need for additional capital to sustain its development initiatives.